HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


L’Oréal earnings

This article was originally published in The Rose Sheet

Executive Summary

Profit before capital gains and losses and after minority interests jumps 19.6% to $1.07 bil. (€1=$.87) in 2001, L'Oréal says in 1Feb. 22 announcement. Growth is attributed to "brand-related initiatives" combined with strong sales in international markets such as China, where sales grew by 26% and Russia, where sales increased 52%, the French beauty marketer adds. During the year, product initiatives, such as Garnier Lumia hair color and Lancôme Absolue skin care successfully targeted new consumers, the company notes. Matrix, Carson and Kiehl's brands, acquired in 2000, produced sales of $455.3 mil. in 2001. L'Oreal released 2001 consolidated sales of $12.06 bil., up 8.4%, in January (2"The Rose Sheet" Jan. 28, 2002, In Brief)...

You may also be interested in...

L’Oréal sales

North American cosmetics sales increase 14% to $3.75 bil. (€1=$.88) in 2001 including currency effects, French firm reports Jan. 23. Sales in Western Europe were up 5.6%, while sales in the rest of the world rose 8.8%. Consolidated sales reached $12.06 bil., representing an increase of 8.4% over the prior year. L'Oréal acquired Biomedic skin care and Colorama makeup in 2001 (11"The Rose Sheet" May 14, 2001, p. 6 and 22"The Rose Sheet" July 9, 2001, In Brief)...

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts